{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T19:00:53Z","timestamp":1790103653802,"version":"4.0.1"},"reference-count":29,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"38","license":[{"start":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T00:00:00Z","timestamp":1789689600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,9,18]]},"abstract":"<jats:sec>\n                    <jats:title\/>\n                    <jats:p>\n                      China remains a high-burden country for rifampicin-resistant tuberculosis. The treatment of drug-resistant tuberculosis is expensive, with many adverse drug reactions and greater difficulty to cure. Searching for appropriate treatment regimens is urgent. A retrospective study was conducted on HIV-negative patients aged 18 to 60 years with rifampicin- or multidrug- or pre-extensively drug-resistant tuberculosis (RR\/MDR\/Pre-XDR-TB) at the Public Health Clinical Center of Chengdu, China from May 1, 2018 to July 31, 2022. Patients were divided into 3 groups: linezolid (Lzd) + bedaquiline (Bdq) containing group (regimen A), Lzd + delamanid (Dlm) containing group (regimen B), and Lzd + other drugs containing group (regimen C, not containing Bdq or Dlm). A total of 142 RR\/MDR\/Pre-XDR-TB patients were included (63 in regimen A, 34 in regimen B, and 45 in regimen C). At 2 months of treatment, 1 patient was lost to follow-up in regimen A and regimen C, respectively. At 6 months of treatment, 3 patients were lost to follow-up in regimen A and regimen C, respectively, and 2 patients were lost to follow-up in regimen B. The sputum culture conversion rates of RR\/MDR\/Pre-XDR-TB patients in regimen A, B, and C at the end of 2 and 6 months were (72.6% [45\/62] vs 64.7% [22\/34] vs 18.2% [8\/44]) and (95.0% [57\/60] vs 90.6% [29\/32] vs 81.0% [34\/42]), respectively (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2005&lt;\u2005.05). 88.2% (30\/34) of the Dlm group used Lzd-Dlm-clofazimine (Cfz)-cycloserine (Cs) containing regimens. 7.9% (5\/63) of patients stopped using Bdq due to corrected QT interval by Fredericia\u2005&gt;500\u2009ms. 2.9% (1\/34) of patients with corrected QT interval by Fredericia prolongation and an increase of 88\u2009ms from baseline stopped Dlm. No patient experienced any malignant heart disease events. Due to related adverse events of Lzd, 14.1% (20\/142) reduced Lzd dosage and 6.3% (9\/142) had permanent discontinuation of Lzd. 6-month Lzd\u2005+\u2005(Bdq or Dlm) containing regimens were associated with favorable early culture conversion and showed good safety among HIV-negative patients aged 18 to 60 years with RR\/MDR\/Pre-XDR-TB. Lzd-Dlm-Cfz-Cs containing regimens may serve as promising candidate regimens for future research on rifampicin-resistant tuberculosis. Multicenter prospective studies with longer follow-up and definitive treatment outcomes are needed to establish comparative effectiveness or treatment superiority of these regimens.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/md.0000000000050758","type":"journal-article","created":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T17:01:50Z","timestamp":1789750910000},"page":"e50758","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["The safety and efficacy of different anti-tuberculosis regimens containing Lzd for RR\/MDR\/Pre-XDR-TB patients in China"],"prefix":"10.1097","volume":"105","author":[{"given":"Xian-Zhen","family":"Tang","sequence":"first","affiliation":[{"name":"Department of Tuberculosis, Public Health Clinical Center of Chengdu, Chengdu, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yao","family":"Ma","sequence":"additional","affiliation":[{"name":"Department of Tuberculosis, Public Health Clinical Center of Chengdu, Chengdu, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shen-Jie","family":"Tang","sequence":"additional","affiliation":[{"name":"Beijing Chest Hospital, Capital Medical University, Beijing Tuberculosis and Thoracic Tumour Research Institute, Beijing, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qing","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Tuberculosis, Public Health Clinical Center of Chengdu, Chengdu, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li-Ping","family":"Zou","sequence":"additional","affiliation":[{"name":"Department of Tuberculosis, Public Health Clinical Center of Chengdu, Chengdu, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-Yan","family":"Fu","sequence":"additional","affiliation":[{"name":"Department of Tuberculosis, Public Health Clinical Center of Chengdu, Chengdu, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Huang","sequence":"additional","affiliation":[{"name":"Department of Tuberculosis, Public Health Clinical Center of Chengdu, Chengdu, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-1345-9496","authenticated-orcid":false,"given":"Gui-Hui","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Tuberculosis, Public Health Clinical Center of Chengdu, Chengdu, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R2-20260922","doi-asserted-by":"crossref","first-page":"e0270003","DOI":"10.1371\/journal.pone.0270003","article-title":"Risk factors for multidrug-resistant tuberculosis: a worldwide systematic review and meta-analysis.","volume":"17","author":"Xi","year":"2022","journal-title":"PLoS One"},{"key":"R3-20260922","doi-asserted-by":"crossref","first-page":"e0270272","DOI":"10.1371\/journal.pone.0270272","article-title":"Prevalence of multidrug-resistant tuberculosis in East Africa: a systematic review and meta-analysis.","volume":"17","author":"Molla","year":"2022","journal-title":"PLoS One"},{"key":"R4-20260922","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/j.jinf.2018.10.004","article-title":"Risk factors of multidrug-resistant tuberculosis: a global systematic review and meta-analysis.","volume":"77","author":"Pradipta","year":"2018","journal-title":"J Infect"},{"key":"R5-20260922","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1111\/phn.12582","article-title":"Risk factors of multidrug-resistant tuberculosis in China: a meta-analysis.","volume":"36","author":"Feng","year":"2019","journal-title":"Public Health Nurs"},{"key":"R6-20260922","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1002\/med.21602","article-title":"An overview of new antitubercular drugs, drug candidates, and their targets.","volume":"40","author":"Bahuguna","year":"2020","journal-title":"Med Res Rev"},{"key":"R7-20260922","doi-asserted-by":"crossref","first-page":"444","DOI":"10.3897\/folmed.62.e48742","article-title":"Linezolid: a promising agent for the treatment of multiple and extensively drug-resistant tuberculosis.","volume":"62","author":"Fermeli","year":"2020","journal-title":"Folia Med (Plovdiv)"},{"key":"R8-20260922","doi-asserted-by":"crossref","first-page":"e00856","DOI":"10.1128\/AAC.00856-18","article-title":"Effect of linezolid plus bedaquiline against mycobacterium tuberculosis in log phase, acid phase, and nonreplicating-persister phase in an in vitro assay.","volume":"62","author":"de Miranda Silva","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"R9-20260922","doi-asserted-by":"crossref","first-page":"645485","DOI":"10.3389\/fimmu.2021.645485","article-title":"Repurposing immunomodulatory drugs to combat tuberculosis.","volume":"12","author":"Fatima","year":"2021","journal-title":"Front Immunol"},{"key":"R10-20260922","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1007\/s40262-021-00997-0","article-title":"Population pharmacokinetics and bayesian dose adjustment to advance TDM of Anti-TB drugs.","volume":"60","author":"Sturkenboom","year":"2021","journal-title":"Clin Pharmacokinet"},{"key":"R11-20260922","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1186\/s12941-016-0156-y","article-title":"Efficacy and safety profile of linezolid in the treatment of multidrug-resistant (MDR) and extensively drug-resistant (XDR) tuberculosis: a systematic review and meta-analysis.","volume":"15","author":"Agyeman","year":"2016","journal-title":"Ann Clin Microbiol Antimicrob"},{"key":"R12-20260922","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/S1474-4422(21)00435-X","article-title":"Tuberculous meningitis: progress and remaining questions.","volume":"21","author":"Huynh","year":"2022","journal-title":"Lancet Neurol"},{"key":"R15-20260922","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.3390\/antibiotics12091389","article-title":"The efficacy and safety of bedaquiline in the treatment of pulmonary tuberculosis patients: a systematic review and meta-analysis.","volume":"12","author":"Tong","year":"2023","journal-title":"Antibiotics (Basel)"},{"key":"R16-20260922","doi-asserted-by":"crossref","first-page":"e20210384","DOI":"10.36416\/1806-3756\/e20210384","article-title":"Bedaquiline-containing regimens and multidrug-resistant tuberculosis: a systematic review and meta-analysis.","volume":"48","author":"Hatami","year":"2022","journal-title":"J Bras Pneumol"},{"key":"R17-20260922","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1186\/s12879-022-07693-9","article-title":"Effectiveness and safety of bedaquiline-containing regimens for treatment on patients with refractory RR\/MDR\/XDR-tuberculosis: a retrospective cohort study in East China.","volume":"22","author":"Zhang","year":"2022","journal-title":"BMC Infect Dis"},{"key":"R18-20260922","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1016\/S0140-6736(18)31644-1","article-title":"Treatment correlates of successful outcomes in pulmonary multidrug-resistant tuberculosis: an individual patient data meta-analysis.","volume":"392","author":"Ahmad","year":"2018","journal-title":"Lancet"},{"key":"R19-20260922","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1159\/000528274","article-title":"New and repurposed drugs for the treatment of active tuberculosis: an update for clinicians.","volume":"102","author":"Aguilar Diaz","year":"2023","journal-title":"Respiration"},{"key":"R20-20260922","doi-asserted-by":"crossref","first-page":"e0000818","DOI":"10.1371\/journal.pgph.0000818","article-title":"Comparative effectiveness of adding delamanid to a multidrug-resistant tuberculosis regimen comprised of three drugs likely to be effective.","volume":"3","author":"Rodriguez","year":"2023","journal-title":"PLOS Glob Public Health"},{"key":"R21-20260922","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/S2213-2600(18)30426-0","article-title":"Efficacy and safety of delamanid in combination with an optimised background regimen for treatment of multidrug-resistant tuberculosis: a multicentre, randomised, double-blind, placebo-controlled, parallel group phase 3 trial.","volume":"7","author":"von Groote-Bidlingmaier","year":"2019","journal-title":"Lancet Respir Med"},{"key":"R22-20260922","doi-asserted-by":"crossref","first-page":"779","DOI":"10.2217\/fmb-2019-0309","article-title":"Bedaquiline and delamanid for drug-resistant tuberculosis: a clinician\u2019s perspective.","volume":"15","author":"Guglielmetti","year":"2020","journal-title":"Future Microbiol"},{"key":"R23-20260922","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.ijid.2023.04.392","article-title":"Epidemiology of extensively drug-resistant tuberculosis among patients with multidrug-resistant tuberculosis: a systematic review and meta-analysis.","volume":"132","author":"Diriba","year":"2023","journal-title":"Int J Infect Dis"},{"key":"R24-20260922","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1186\/s12879-021-06024-8","article-title":"Molecular characterization of multidrug-resistant tuberculosis against levofloxacin, moxifloxacin, bedaquiline, linezolid, clofazimine, and delamanid in southwest of China.","volume":"21","author":"Zheng","year":"2021","journal-title":"BMC Infect Dis"},{"key":"R25-20260922","doi-asserted-by":"crossref","first-page":"2336","DOI":"10.1093\/cid\/ciz1107","article-title":"Clinical outcomes among patients with drug-resistant tuberculosis receiving bedaquiline- or delamanid-containing regimens.","volume":"71","author":"Kempker","year":"2020","journal-title":"Clin Infect Dis"},{"key":"R26-20260922","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1093\/cid\/ciac876","article-title":"Efficacy and tolerability of concomitant use of bedaquiline and delamanid for multidrug- and extensively drug-resistant tuberculosis: a systematic review and meta-analysis.","volume":"76","author":"Holmgaard","year":"2023","journal-title":"Clin Infect Dis"},{"key":"R27-20260922","doi-asserted-by":"crossref","first-page":"1183597","DOI":"10.3389\/fcimb.2023.1183597","article-title":"Advances of new drugs bedaquiline and delamanid in the treatment of multi-drug resistant tuberculosis in children.","volume":"13","author":"Zhu","year":"2023","journal-title":"Front Cell Infect Microbiol"},{"key":"R28-20260922","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1007\/s40265-022-01817-w","article-title":"The struggle to end a millennia-long pandemic: novel candidate and repurposed drugs for the treatment of tuberculosis.","volume":"82","author":"Edwards","year":"2022","journal-title":"Drugs"},{"key":"R29-20260922","doi-asserted-by":"crossref","first-page":"S327","DOI":"10.1093\/cid\/ciy625","article-title":"Linezolid-based regimens for multidrug-resistant tuberculosis (TB): a systematic review to establish or revise the current recommended dose for TB treatment.","volume":"67","author":"Bolhuis","year":"2018","journal-title":"Clin Infect Dis"},{"key":"R30-20260922","doi-asserted-by":"crossref","first-page":"e0138121","DOI":"10.1128\/AAC.01381-21","article-title":"Linezolid population pharmacokinetics in South African adults with drug-resistant tuberculosis.","volume":"65","author":"Abdelwahab","year":"2021","journal-title":"Antimicrob Agents Chemother"},{"key":"R31-20260922","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/s40249-021-00819-2","article-title":"Bedaquiline-containing regimens in patients with pulmonary multidrug-resistant tuberculosis in China: focus on the safety.","volume":"10","author":"Gao","year":"2021","journal-title":"Infect Dis Poverty"},{"issue":"Suppl 1","key":"R32-20260922","doi-asserted-by":"crossref","first-page":"S90","DOI":"10.1016\/j.ijid.2022.02.043","article-title":"Delamanid-containing regimens and multidrug-resistant tuberculosis: a systematic review and meta-analysis.","volume":"124","author":"Nasiri","year":"2022","journal-title":"Int J Infect Dis"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/MD.0000000000050758","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T18:03:59Z","timestamp":1790100239000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/MD.0000000000050758"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,18]]},"references-count":29,"journal-issue":{"issue":"38","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000050758","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,18]]},"assertion":[{"value":"2024-07-23","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-09-02","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}